Dr. James W. Kress is President of The KressWorks Foundation, a non-profit foundation dedicated to the performance Scientific Research in the Public Interest using Computational Chemistry and related methods and technologies. The Foundation's current primary focus is in the area of Chemical Biophysics in the Quantitative Analysis of Biological Celluar Systems. The KressWorks Foundation receives and administers funds for physical and chemical scientific research performed at the atomistic, molecular and bulk system levels for the characterization of and application to solutions of chemical, physical chemical, physical bio-chemical and physical cell biology problems necessary to understand and cure diseases and other problems of scientific interest.
Dr. Kress is also Chairman and Chief Executive Officer of KressWorks, a Technology Consulting Firm that specializes in the application of Information Technology Systems and methods to the solution of Engineering, Science, and Business Challenges.
Prior to forming KressWorks and The KressWorks Foundation, Dr. Kress was a Business Process Consultant for Hewlett-Packard. During this engagement he led the Strategic Planning Tower of HP’s GSC-10 AIMD engagement with GM’s GPD Information Systems and Services (IS&S) group in Warren Michigan. His responsibilities included the management of a global application portfolio consisting of multiple software packages from multiple suppliers, providing assistance in the IS&S Strategic Planning Process, and management of the IT competitive analysis (software and associated processes) of GM versus its competition, world-wide.
Before joining Hewlett-Packard, Dr. Kress worked for a number of companies of varying sizes, most notably:
Innovision Technologies, Inc, where he was an Information Technology Strategic Technical Analyst, TRW Automotive Electronics North America, as the Manager of the Engineering Systems Department, Sensors, Inc., Director of Engineering, Saturn Electronics And Engineering as the Director of the Technology Center (with full Profit and Loss responsibility), First Technology Safety Systems, as Vice President of Engineering, and, initially, Ford Motor Company, as the Chief Sensor Planner, Business Planning Office, Electronics Division; Supervisor, Thick Film Based Powertrain Sensors Section, Electronics Division; Supervisor, Advanced Powertrain, Electrical and Electronics Division; Design Engineer, Advanced Sensors and Actuators Section, Electrical and Electronics Division; Research Scientist, Scientific Research Laboratory.
Among some of his most notable Technical accomplishments are the integration of Quantum Mechanics/ Molecular Mechanics mixed methodologies (with Dr. Alex Granovsky) into PC GAMESS (currently known as FireFly), publication of over 15 papers (citation index) in peer reviewed journals on a wide variety of scientific and engineering topics, holder of 3 patents (2 more pending), design, construction implementation and application of a variety of High Performance Computing Clusters using a variety of network interconnect (Ethernet, Infiniband) and operating systems (Linux, Windows), application of a variety of Computational Chemistry and Visualization methodologies and software packages to the resolution of problems of Chemical, Spectroscopic, Material Science, and Biochemical/ Biological interest.
He was also responsible for the design, development and application of the first direct 3D Computer Aided Tomography System (for automotive and medical applications); the development of silicon micromachining technology for automotive actuator applications; leader of team that invented and applied a previously unavailable, complete, on-board Powertrain software/ hardware development system including performance analyzers, compilers, data acquisition, high speed interface circuits/ boards, etc.
Some of his most notable Business accomplishments have been the successful operation of the Profit and Loss Technology Center at Saturn Electronics and Engineering; the development and implementation of a complete Sensor Strategic and Business Plan at Ford that included a technology plan as well as financial analyses that determined engineering and manufacturing head count, facilities and tooling, product portfolio, product cost analysis, investment, staffing, organization, and projected business evolution; at Sensors Inc. he initiated automotive gas analysis product development and application relationship with CETESB, the Brazilian equivalent of the US EPA; he facilitated the design and implementation of complete product development processes for a number of companies, including Ford and TRW, and (again at Ford) he developed and helped implement a Strategic Technology Plan for Ford’s divestiture of its extensive portfolio of Intellectual Property and know-how in the area of Technical Ceramics.
Dr. Kress holds a Bachelor of Science in Chemistry, Ball State University; Two Research Fellowships in Synthetic and Physical Organic Chemistry for his Junior and Senior Years while at Ball State; a Doctor of Philosophy in Physical Chemistry, University of Notre Dame with a summer Internship at the Almaden IBM Research Laboratory in San Jose, CA; a National Science Foundation US-USSR Postdoctoral Fellowship in Catalysis, University of Notre Dame; and a Radiation Laboratory Postdoctoral Fellowship in Atmospheric Chemistry, University of Notre Dame.
Dr. Kress is a member of the American Society of Clinical Oncologists (ASCO), The American Association for Cancer Research (AACR), The American Chemical Society (ACS), The Institute of Electrical and Electronics Engineers (IEEE) and the American Physical Society (APS).
Dr. Kress has continued his education to expand his knowledge of the biology, chemistry and physics required to meet the goals of The Kressworks Foundation. His continuing education includes the following:
The overall goal of this course is to teach a student how to relate the chemical structure of a drug to its biological function. Subject matter includes discussions about proteins, pharmacokinetics & metabolism, chemical diversity, and finally lead discovery & lead optimization. Proteins are the molecules that control the biological pathways in the body. And by affecting proteins with drugs, that's how we can help improve patients and their disease state. Pharmacokinetics describes how does a drug get into the body, how does it get distributed through the body. Then metabolism describes in part how that drug is then broken down and eliminated from the body. You may not think of chemical diversity diversity as being a chemistry issue, but it absolutely is. And this is an important topic as well for drug discovery. Lead discovery and lead optimization discusses how we find molecules that have activity against the disease state. And then how do we improve their activity so they hopefully can be approved as pharmaceuticals.
How does a research innovation turn into a therapeutic medicine that health care providers prescribe to patients? This course explores the process, challenges and issues in developing pharmaceutical products. Drug development is a dynamic field where innovation and entrepreneurship are necessary to keep up with health care expectations, strict regulations and tightening development budgets. An overview of drug development, approval, and consumer issues will be presented and discussed in the context of research practices, science, marketing, public welfare and business.
UTAustinX: UT.4.01x Take Your Medicine was developed by Dr. Janet Walkow and her team at the College of Pharmacy, The University of Texas at Austin. The course was completed on December 4, 2013 with a score of 100%. Syllabus
This course introduces the student to contemporary Systems Biology focused on mammalian cells, their constituents and their functions. Biology is moving from molecular to modular. As our knowledge of our genome and gene expression deepens and we develop lists of molecules (proteins, lipids, ions) involved in cellular processes, we need to understand how these molecules interact with each other to form modules that act as discrete functional systems. These systems underlie core subcellular processes such as signal transduction, transcription, motility and electrical excitability. In turn these processes come together to exhibit cellular behaviors such as secretion, proliferation and action potentials.Examples will be discussed to demonstrate “how” cell- level functions arise and “why” mechanistic knowledge allows us to predict cellular behaviors leading to disease states and drug responses.
The course was taught by Dr. Ravi Iyengar who is a Professor in the Department of Pharmacology and Systems Therapeutics at Icahn School of Medicine at Mount Sinai in New York City. He is a member and Director of Systems Biology Center New York a transdisciplinary center funded in part by the NIGMS. His expertise in signal transduction and cell signaling networks and in Systems Biology. The course was completed with High Distinction July 22, 2013. Syllabus
7.00x – The Secret of Life we explored biochemistry, genetics, molecular biology, recombinant DNA technology and genomics, and rational medicine within a well defined context of decomposing Biological Function into its basic components and their inter-relationships. The course was taught by Eric Lander who is a Professor of Biology at MIT and Professor of Systems Biology at Harvard Medical School. He is the President and Founding Director of the Broad Institute of MIT and Harvard. Lander was one of the principal leaders of the Human Genome Project. This course was completed with certification (top 5% of the class) in June 2013. Syllabus
A semiclassical approach to understanding microelectronic device operation and related electron, heat, and light transport. Part I is designed to convey in readily accessible language, the key concepts developed in the last 20 years, which constitute the fundamentals of nanoelectronics and mesoscopic physics. Syllabus. Completed with High Distinction in March 2012.
A Quantum Mechanics approach to the topics discussed in Part I with heavy emphasis on the derivation, understanding, and application of Non-Equilibrium Greens Functions for Quantum Transport Theory - universally applicable to Transport in atomistic systems of all types, electrical, chemical, biological, etc. Part II provides an introduction to more advanced topics including the Non-- Equilibrium Green’s Function (NEGF) method widely used to analyze quantum transport in nanoscale devices. Syllabus. Completed with High Distinction in May 2012.
With additional courses scheduled later this year in Systems Biology - Network Analysis and Systems Biology - Simulation Methods.